Clinical Trial Update: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) [Phase 3]

View source ↗

Summary

Phase 3 evaluation of adding AL3818 to standard platinum-based chemotherapy for recurrent or metastatic gynecologic carcinomas is in progress, with an unknown s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Carcinoma
• Endometrial Carcinoma
• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Peritoneal Carcinoma

Drugs mentioned

• AL3818

Snippet

Sponsor: Advenchen Laboratories, LLC | Conditions: Endometrial Carcinoma, Ovarian Carcinoma | Phase 3 | Status: UNKNOWN